Login to Your Account



Santhera sinks on negative CHMP vote for Raxone in DMD; firm plans appeal

By Nuala Moran
Staff Writer

Friday, September 15, 2017

LONDON – Shares in Santhera Pharmaceutical AG crashed by 58 percent on Friday morning after the EMA gave a thumbs down to Raxone as a treatment for the respiratory complications of Duchenne muscular dystrophy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription